Published: Jul 26, 2024, 05:50 IST | Updated: Jul 26, 2024, 05:50 IST
Europe's medicines watchdog on Friday rejected a request to market a new Alzheimer's disease treatment, saying the risks of the medicine's side effects, including potential brain bleeding, outweighed the benefits. Watch in for more details!